#United States #Chicago #Taiho Oncology #Zipalertinib #ASCO 2025

Taiho Oncology Set to Showcase Research at ASCO 2025

Taiho Oncology, Inc., known for innovating treatments for hematologic malignancies and solid tumors, is gearing up to unveil new data at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for May 30 to June 3 at McCormick Place in Chicago. The company will present findings from five studies, including two oral presentations that are highly anticipated in the oncology field.

The first of the oral presentations will focus on zipalertinib, a promising investigational drug aimed at treating non-small cell lung cancer (NSCLC) that features EGFR exon 20 insertion mutations. This presentation is important as it follows patients who had received prior platinum-based chemotherapy and may offer insights into potential advances in NSCLC treatment options.

The second oral presentation will spotlight ASTX727 (oral decitabine-cedazuridine), which has received FDA approval for myelodysplastic syndromes (MDS) and is being explored in combination with venetoclax for patients diagnosed with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. These presentations allow researchers and clinicians alike to explore how advancements in therapy protocols could improve outcomes for patients suffering from these aggressive cancers.

In addition to these oral discussions, Taiho will share data from three real-world studies examining the effectiveness and safety of two FDA-approved therapies: trifluridine and tipiracil in conjunction with bevacizumab for patients with metastatic colorectal cancer and futibatinib for treating cholangiocarcinoma. Such real-world evidence is crucial for understanding the impact of treatments in broader patient populations, beyond the controlled environments of clinical trials.

Harold Keer, MD, PhD, Chief Medical Officer at Taiho Oncology, expressed enthusiasm about the opportunity to engage with leaders in oncology at ASCO, highlighting how these presentations aim to foster discussions on innovative therapies and real-world treatment outcomes.

Presentation Details

Detailed information on the oral presentations includes:

• - Efficacy of zipalertinib in NSCLC patients with EGFR exon 20 insertion mutations: This session will take place on June 1, 2025, from 8 a.m. to 11 a.m. CDT at the Arie Crown Theater, featuring Dr. Helena A. Yu from Memorial Sloan Kettering Cancer Center.
• - An all-oral regimen of decitabine-cedazuridine plus venetoclax in patients with newly diagnosed acute myeloid leukemia: This will be presented on June 2, 2025, from 3 p.m. to 6 p.m. CDT, with Dr. Amer Zeidan from Yale Cancer Center leading the discussion.

Alongside these exciting oral sessions, Taiho has also prepared compelling poster presentations emphasizing real-world treatment patterns. These findings aim to shed light on how approved therapies are utilized in practice and the outcomes they deliver, resonating the company's ongoing commitment to ensure that scientific advancements translate effectively into clinical practice.

As Taiho Oncology approaches ASCO 2025, the focus remains on providing innovative cancer treatments that not only advance therapeutic options but also aim to improve quality of life for patients and their families. For many, these presentations are awaited events that could redefine approaches in cancer treatment and research, holding promise for better patient outcomes.